|
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Clinical research trials and Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors. Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors  Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
For Condition: Solid Tumor,Genetic Condition,Brain Tumor
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , University of Pittsburgh Cancer Institute
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells. Combining calcitriol with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of calcitriol combined with carboplatin in treating patients who have advanced solid tumors.
Details: OBJECTIVES: I. Determine the maximum tolerated doses of calcitriol and carboplatin, when given in combination, in patients with advanced solid tumors. II. Determine the toxic effects of this regimen in these patients. III. Determine the effect of calcitriol on the pharmacokinetics of carboplatin in these patients. IV. Correlate the pharmacokinetics of carboplatin with the myelosuppression following this regimen in these patients. V. Determine the safety and efficacy of this regimen in patients with malignant glioma. PROTOCOL OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (brain tumor vs other solid tumor) and accrued in parallel. Patients are assigned to one of two treatment groups. Group 1: Patients receive carboplatin IV over 20-30 minutes on day 1 and calcitriol subcutaneously (SC) or orally daily on days 2-4 for the first course only. For subsequent courses, patients receive calcitriol SC or orally daily on days 1-3 and carboplatin IV over 20-30 minutes on day 3. Group 2: Patients receive calcitriol SC or orally daily on days 1-3 and carboplatin IV over 20-30 minutes on day 3 for the first, third, and subsequent courses. For the second course only, patients receive carboplatin IV over 20-30 minutes on day 1 and calcitriol SC or orally daily on days 2-4. In both groups, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Sequential dose escalation of calcitriol is followed by sequential dose escalation of carboplatin. Cohorts of 3-6 patients receive escalating doses of calcitriol and then carboplatin until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: Approximately 18-50 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed advanced solid tumor that is not curable by standard therapy, including glioma and other brain tumors - Brain metastases allowed following definitive radiotherapy --Prior/Concurrent Therapy-- - Biologic therapy: At least 4 weeks since prior biologic therapy (regional or systemic) - Chemotherapy: At least 4 weeks since prior chemotherapy - Endocrine therapy: No concurrent glucocorticoids as antiemetics; Concurrent exogenous glucocorticoids allowed for treatment of gliomas or other brain tumors - Radiotherapy: See Disease Characteristics; At least 4 weeks since prior radiotherapy - Surgery: Not specified - Other: Dietary calcium intake of no more than 200-250 mg/day beginning 48 hours before each course and continuing for 7 days; No concurrent dairy products, green leafy vegetables, molasses, baking powder, fortified cereals, and dry peas and beans --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 8 weeks - Hematopoietic: Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 1.5 mg/dL; SGOT no greater than 4 times normal - Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min AND Creatinine no greater than 2.0 mg/dL; Calcium no greater than 10.5 mg/dL - Cardiovascular: No unstable angina; No symptomatic coronary artery disease - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use 2 forms of barrier contraception AND 1 form of hormonal contraception for at least 1 week before, during, and for at least 2 weeks after study; No active infection; No other concurrent serious condition
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RameshRamanathan, Study Chair, University of Pittsburgh Cancer Institute
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213-3489
United States
Additional Information:
Study ID Numbers: CDR0000068374; PCI-IRB-970532,NCI-G00-1885,PCI-97-004
Study Start Date: January 1996
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00008086
Other Brain Tumor Studies:
1. Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
2. STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
3. Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
4. Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Related Studies:
Other Brain Tumor Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
